BioNTech doubles down on an antibody discovery group, scooping up a new team to play for the mRNA specialist
Whatever BioNTech learned about MAB Discovery’s antibody generator over the past 5 years — and a pair of collaborations — it was enough tire kicking to make the messenger RNA outfit want to go all in.
The German mRNA specialist — which likes to deliver code for therapeutics including antibodies into cells — has struck a deal to buy out the antibody generator group from MAB Discovery. MAB, in turn, will keep its preclinical pipeline and go its own way in drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
